Gabat S, Keller C, Kempe H P, Amiral J, Ziegler R, Ritz E, Bergis K H, Wahl P, Nawroth P
Department of Internal Medicine, University Heidelberg, Germany.
Vasa. 1996;25(3):233-41.
Thrombomodulin (TM), a marker of endothelial cell damage was studied in 183 patients with diabetes mellitus and different stages of complications. Thrombomodulin plasma levels correlated with duration of diabetes in patients with type I and type II diabetes. Thrombomodulin levels were higher in patients with increasing numbers of complications (nephropathy, retinopathy, arterio-occlusive disease, neuropathy). Neither the presence of retinopathy, nor neuropathy alone significantly increased plasma thrombomodulin in patients with similar urinary albumin concentration. The plasma level of thrombomodulin was more prominent in hypertensive than normotensive patients. Multivariate analysis showed that albuminuria is the factor which influences the most the increase of thrombomodulin in serum of diabetic patients.
对183例患有糖尿病及不同并发症阶段的患者进行了血栓调节蛋白（TM）——一种内皮细胞损伤标志物的研究。I型和II型糖尿病患者的血浆血栓调节蛋白水平与糖尿病病程相关。并发症（肾病、视网膜病变、动脉闭塞性疾病、神经病变）数量增加的患者，其血栓调节蛋白水平更高。在尿白蛋白浓度相似的患者中，单独存在视网膜病变或神经病变均未显著增加血浆血栓调节蛋白水平。高血压患者的血浆血栓调节蛋白水平比血压正常的患者更为显著。多变量分析表明，蛋白尿是影响糖尿病患者血清中血栓调节蛋白升高的最主要因素。
